中国部分地区非酒精性脂肪肝病的流行情况

吴挺丰; 廖献花; 钟碧慧

doi:10.3969/j.issn.1001-5256.2020.06.039

中国部分地区非酒精性脂肪肝病的流行情况

DOI: 10.3969/j.issn.1001-5256.2020.06.039

中山大学第一附属医院消化内科

基金项目:

国家自然科学基金(81870404,81670518)；广东省科技计划项目(2013B021800290,2014A020212118,2017A020215015)；广东省医学科学技术研究基金(A2019496)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 1704
- HTML全文浏览量: 118
- PDF下载量: 414
- 被引次数: 0
出版历程
- 收稿日期: 2019-12-26
- 出版日期: 2020-06-20

Epidemiology of nonalcoholic fatty liver disease in some regions of China

Department of Gastroenterology,The First Affiliated Hospital of Sun Yat-Sen University

Research funding:

摘要

摘要:
非酒精性脂肪性肝病(NAFLD)已经取代病毒性肝炎成为全球第一大慢性肝病。国内目前诊断NAFLD仍以腹部B超为主要手段。过去20年内,国内研究显示人群的NAFLD患病率为13%～43%,且NAFLD患病率呈逐年上升趋势,每年新发NAFLD的人数比例约为4%,其中非肥胖NAFLD也有一定的患病率。不同区域人群患病率存在显著差异,经济水平更为发达、居民生活习惯更接近西方社会生活习惯的东南沿海地区,NAFLD患病率更高。2型糖尿病、肥胖症、高脂血症、高尿酸血症、高血压等代谢异常疾病是NAFLD患病的危险因素。我国仍然需要更严谨更大样本的大范围流行病学调查来明确NAFLD的患病因素,以及进一步加大对NAFLD的诊治和预防的宣传力度。
- 非酒精性脂肪肝性肝病 /
- 患病率 /
- 发病率 /
- 代谢疾病
Abstract:
Nonalcoholic fatty liver disease( NAFLD) has replaced viral hepatitis and become the most important chronic liver disease in the world. Abdominal ultrasound remains the main method for the diagnosis of NAFLD in China. The studies in China showed that in the last two decades,the prevalence rate of NAFLD was 13%-43% and tended to increase year by year,and the new cases accounted for about 4%each year,with a certain proportion of patients with non-obese NAFLD. There is a significant difference in prevalence rate between the populations from different regions,with a higher prevalence rate of NAFLD in the well-developed southeast coastal regions where people have a similar lifestyle to those in Western countries. Metabolic disorders,such as type 2 diabetes,obesity,hyperlipidemia,hyperuricemia,and hypertension,are risk factors for NAFLD. National-wide large-sample epidemiological investigation is still needed in China to help support the diagnosis,treatment,and prevention of NAFLD.
- non-alcoholic fatty liver disease /
- prevalence /
- incidence /
- metabolic diseases

HTML全文

参考文献(38)

[1] CHALASANI N,YOUNOSSI Z,LAVINE JE,et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2018,67(1):328-357.

[2] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology,2016,64(1):73-84.

[3] YOUNOSSI Z,TACKE F,ARRESE M,et al. Global Perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology,2019,69(6):2672-2682.

[4] ESTES C,ANSTEE QM,ARIAS-LOSTE MT,et al. Modeling NAFLD disease burden in China,France,Germany,Italy,Japan,Spain,United Kingdom,and United States for the period2016-2030[J]. J Hepatol,2018,69(4):896-904.

[5] JIMBA S,NAKAGAMI T,TAKAHASHI M,et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults[J]. Diabet Med,2005,22(9):1141-1145.

[6] FARRELL GC,LARTER CZ. Nonalcoholic fatty liver disease:From steatosis to cirrhosis[J]. Hepatology,2006,43(2 Suppl1):s99-s112.

[7] VERNON G,BARANOVA A,YOUNOSSI ZM. Systematic review:The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J]. Aliment Pharmacol Ther,2011,34(3):274-285.

[8] SHEN L,FAN JG,SHAO Y,et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai:An epidemiological survey[J]. World J Gastroenterol,2003,9(5):1106-1110.

[9] ZHOU YJ,LI YY,NIE YQ,et al. Prevalence of fatty liver disease and its risk factors in the population of South China[J].World J Gastroenterol,2007,13(47):6419-6424.

[10] YAN H,LU XL,LUO JY,et al. Epidemiological analysis of alcoholic and non-alcoholic fatty liver in Shanxi and Gansu province[J]. Chin J Gastroenterol Hepatol,2007,16(4):347-350,353.(in Chinese)延华，鲁晓岚，罗金燕，等．陕、甘两省酒精性与非酒精性脂肪肝流行病学分析[J]．胃肠病学和肝病学杂志，2007,16(4):347-350,353.

[11] SHI XD,WEI Q,HE SM,et al. Epidemiology and analysis on risk factors of non-infectious chronic diseases in adults in northeast China[J]. J Jilin Univ(Med Edit),2011,37(2):379-384.(in Chinese)石晓东，魏琪，何淑梅，等．中国东北地区成人非传染性慢性疾病的流行病学调查及影响因素分析[J]．吉林大学学报(医学版)，2011,37(2):379-384.

[12] SHI L,LIU ZW,LI Y,et al. The prevalence of nonalcoholic fatty liver disease and its association with lifestyle/dietary habits among university faculty and staff in Chengdu[J]. Biomed Environ Sci,2012,25(4):383-391.

[13] WONG VW,CHU WC,WONG GL,et al. Prevalence of nonalcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese:A population study using proton-magnetic resonance spectroscopy and transient elastography[J]. Gut,2012,61(3):409-415.

[14] YAN J,XIE W,OU WN,et al. Epidemiological survey and risk factor analysis of fatty liver disease of adult residents,Beijing,China[J]. J Gastroenterol Hepatol,2013,28(10):1654-1659.

[15] ZHAI HL,WANG NJ,HAN B,et al. Low vitamin D levels and non-alcoholic fatty liver disease,evidence for their independent association in men in East China:A cross-sectional study(Survey on Prevalence in East China for Metabolic Diseases and Risk Factors(SPECT-China)[J]. Br J Nutr,2016,115(8):1352-1359.

[16] LIAO XH,CAO X,LIU J,et al. Prevalence and features of fatty liver detected by physical examination in Guangzhou[J].World J Gastroenterol,2013,19(32):5334-5339.

[17] LI Z,XUE J,CHEN P,et al. Prevalence of nonalcoholic fatty liver disease in mainland of China:A meta-analysis of published studies[J]. J Gastroenterol Hepatol,2014,29(1):42-51.

[18] WILLIAMS CD,STENGEL J,ASIKE MI,et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy:A prospective study[J]. Gastroenterology,2011,140(1):124-131.

[19] SAADEH S,YOUNOSSI ZM,REMER EM,et al. The utility of radiological imaging in nonalcoholic fatty liver disease[J].Gastroenterology,2002,123(3):745-750.

[20] EDDOWES PJ,SASSO M,ALLISON M,et al. Accuracy of Fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease[J]. Gastroenterology,2019,156(6):1717-1730.

[21] JOHNSON NA,WALTON DW,SACHINWALLA T,et al. Noninvasive assessment of hepatic lipid composition:Advancing understanding and management of fatty liver disorders[J].Hepatology,2008,47(5):1513-1523.

[22] XU L,LI P,LU W,et al. Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan[J]. Chin J Hepatol,2016,24(2):108-113.(in Chinese)徐亮，李萍，陆伟，等．FibroScan(R)实施受控衰减参数诊断脂肪肝的价值[J]．中华肝脏病杂志，2016,24(2):108-113.

[23] FAN JG,ZHOU Q,WO QH. Effect of body weight mass and its change on the incidence of nonalcoholic fatty liver disease[J]. Chin J Hepatol,2010,18(9):676-679.(in Chinese)范建高，周琪，沃千红．人体质量指数及其变化与非酒精性脂肪性肝病发病的关系[J]．中华肝脏病杂志，2010,18(9):676-679.

[24] ZHOU YJ,LI YY,NIE YQ,et al. Natural course of nonalcoholic fatty liver disease in southern China:A prospective cohort study[J]. J Dig Dis,2012,13(3):153-160.

[25] LU ZY,SHAO Z,LI YL,et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population:An 8-year follow-up study[J]. World J Gastroenterol,2016,22(13):3663-3669.

[26] WONG VW,WONG GL,YEUNG DK,et al. Incidence of non-alcoholic fatty liver disease in Hong Kong:A population study with paired proton-magnetic resonance spectroscopy[J]. J Hepatol,2015,62(1):182-189.

[27] MARCHESINI G,BRIZI M,BIANCHI G,et al. Nonalcoholic fatty liver disease:A feature of the metabolic syndrome[J].Diabetes,2001,50(8):1844-1850.

[28] LU H,ZENG L,LIANG B,SHU X,XIE D. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease[J]. Arch Med Res,2009,40(7):571-575.

[29] YI M,CHEN RP,YANG R,et al. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with type 2 diabetes in South China[J]. Diabet Med,2017,34(4):505-513.

[30] QURESHI K,ABRAMS GA. Prevalence of biopsy-proven nonalcoholic fatty liver disease in severely obese subjects without metabolic syndrome[J]. Clin Obes,2016,6(2):117-123.

[31] FU CC,CHEN MC,LI YM,et al. The risk factors for ultrasounddiagnosed non-alcoholic fatty liver disease among adolescents[J]. Ann Acad Med Singapore,2009,38(1):15-17.

[32] SHAO C,YE J,LI F,et al. Different predictors of steatosis and fibrosis severity among lean,overweight and obese patients with nonalcoholic fatty liver disease[J]. Dig Liver Dis,2019,51(10):1392-1399.

[33] GAO H,KUANG Z,ZHONG CX,et al. Prevalence and risk factors of nonalcoholic fatty liver disease in patients with chronic hepatitis B receiving antiviral therapy[J]. Chin J Hepatol,2019,27(5):347-351.(In Chinese)高慧，匡哲，钟春秀，等．接受抗病毒治疗的慢性乙型肝炎患者非酒精性脂肪性肝病的患病率及其危险因素分析[J]．中华肝脏病杂志，2019,27(5):347-351.

[34] WANG MM,WANG GS,SHEN F,et al. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors[J]. Dig Dis Sci,2014,59(10):2571-2579.

[35] CHENG YL,WANG YJ,KAO WY,et al. Inverse association between hepatitis B virus infection and fatty liver disease:A large-scale study in populations seeking for check-up[J].PLo S One,2013,8(8):e72049.

[36] WONG VW,WONG GL,CHU WC,et al. Hepatitis B virus infection and fatty liver in the general population[J]. J Hepatol,2012,56(3):533-540.

[37] XIONG J,ZHANG H,WANG Y,et al. Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease:A metaanalysis[J]. Oncotarget,2017,8(63):107295-107302.

[38] PENG D,HAN Y,DING H,et al. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors[J]. J Gastroenterol Hepatol,2008,23(7 Pt1):1082-1088.

施引文献

资源附件(0)

访问统计